GeoVax’s HIV/AIDS human vaccine trials to begin in North and South America
Canadian scientists have discovered a new risk factor for cardiovascular disease and the significance of their discovery was so conclusive that the clinical trial was stopped before its scheduled completion date. The international team of scientists have discovered that having high levels of a particular protein - high-sensitivity C-reactive protein (hs-CRP) - puts patients at
Full Post: New risk factor for heart disease suggests more should be on statins
GeoVax Labs, Inc. has announced that the launch of its Phase 2a Human Vaccine Trials will take place in twelve sites across North and South America.
These trials are conducted in collaboration with The National Institutes of Health (NIH), and the HIV Vaccine Trials Network (HVTN).
“It is of significant importance to report this major development on this very day in which the world commemorates WORLD AIDS DAY. Despite setbacks reported recently with other vaccine trials, our vaccine is progressing and paving the way for a solution that would potentially make this commemorative day more joyful,” commented Dr. Robert McNally, GeoVax’s President and CEO.
Dr. Harriet Robinson, Vice President of Research and Development of GeoVax Labs, Inc., stated, “We feel privileged to be in the position to launch our Phase 2a human trial. Going forward, each clinical site’s review board will start the vaccination process, when deemed appropriate and ready. Accordingly, HVTN’s pharmacy will release the vaccines to each designated institution as directed by each site’s local review board.”
Trial site arrangements and other details of the study were confirmed in a recent meeting held in Seattle, Washington, between the HVTN and GeoVax’s scientific personnel. The Phase 2a human clinical trial will involve 150 vaccinees and 75 placebo (control) participants. The vaccine regimen employs a two-component “prime-boost strategy.” Trial participants will first be administered a GeoVax HIV-1 DNA vaccine which “primes” the immune system followed by the second vaccine, GeoVax’s HIV-1 MVA (Modified Vaccinia Virus) boost. Both vaccines express the three major proteins of the AIDS virus. These proteins mimic more than 50% of the components of the AIDS virus (HIV-1) but cannot cause AIDS. GeoVax AIDS vaccines are designed to prevent HIV-1 virus infection which causes Acquired Immunodeficiency Disease (AIDS).
The Seattle meeting also achieved further progress with GeoVax’s therapeutic trial. Information on this and other developments will be reported in a timely fashion in the near future.
Vical Incorporated has announced that the company’s Vaxfectin-formulated H5N1 pandemic influenza DNA vaccines induced T-cell responses against a matching strain of influenza virus and demonstrated cross-clade antibody responses against a different strain in a Phase 1 clinical trial. The company previously reported that the vaccines had achieved potentially protective levels of antibody responses in
Full Post: Vaxfectin-formulated H5N1 pandemic influenza achieves T-cell responses and cross-clade reactivity in humans
Results from the Step study, a test-of-concept efficacy study of a Merck & Co., Inc. HIV vaccine candidate, were published online in two papers in The Lancet this week. These analyses of the Step study are being conducted, presented and published to inform the continued search for an effective HIV vaccine. The two analyses, one
Full Post: Analyses of Merck’s HIV vaccine ‘Step’ study
EpiVax, Inc., a leader in the field of computational immunology, announced today that it has received a grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to optimize delivery of an HIV vaccine. NIAID will provide EpiVax with $390,000 over two years for the
Full Post: EpiVax receives grant for $390,000 to optimize HIV vaccine delivery
Barr Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted for review Duramed Pharmaceuticals, Inc.’s Adenovirus Types 4 and 7 Live Oral Vaccines Biologics License Application (BLA). These oral vaccines represent Barr’s first in-house biologics development initiative and demonstrate the Company’s ability to develop, manufacture and conduct clinical trials for
Full Post: FDA to review Barr Pharmaceutical’s BLA for adenovirus type 4 and 7 live oral vaccines
The University of Maryland, Baltimore (UMB) has licensed a pediatric vaccine against Shigella bacteria to PATH, an international nonprofit group, to support clinical trials, with the goal of developing a vaccine suitable for children in resource-poor countries. Each year, an estimated 1.1 million people die from Shigella infections, a major cause of diarrhea and dysentery,
Full Post: Live oral Shigella vaccine licensed to PATH